

ISSN: 1674-0815

cjhmonline.com

Chinese Journal of
Health Management

Chinese Medical Association



Cardio-protective Potential of *Ocimum sanctum* (Tulsi): A Review of Experimental and Clinical Evidence

Praveen Rao¹, Poorva², M. Mubeen³, Arvind Negi⁴, Prateek Pandey⁵, Rudhali Lilhare⁶, Setu Visavadia⁷, Santosh Kumar Bhatted⁸, Divaker Shukla⁹, Neetu Vishwakarma¹⁰, Mahesh Kumar Posa¹¹, Sudhanshu Kumar Jha^{8*}, Kishan Singh⁸

¹Department of Pharmacology, LN College of Pharmacy, Mahendergarh, India

²Department of Pharmacy, Lords University, Alwar, India

²Krishna college of pharmacy, Kosli (Rewari), India

³Dept of Pharmacognosy, Sri Ramachandra Faculty of Pharmacy, SRIHER (DU) Porur,

⁴Dept of Pharmacognosy, JBIT College of Pharmacy, Chakrata Road, Shankarpur, Dehradun Uttarakhand-248197, India

⁵Department of Pharmacology, United Institute of Pharmacy, Naini, Prayagraj- 211010, Uttar Pradesh, India

⁶Department of Pharmacology, Gondia college of Pharmacy, Chulod, Gondia 441601, India

⁷Department of Chemical Science, Parul Institute of applied Sciences, Parul University, Vadodara, India

⁸All India Institute of Ayurveda, Sarita Vihar, Government of India New Delhi, India.

⁹Department of Pharmacognosy and Phytochemistry, Pharmacy Academy, Faculty of Pharmacy, IFTM University, Lodhipur-Rajput, Pakbara, Delhi Road, Moradabad-244102, Uttar Pradesh, India

¹⁰Sagar Institute of Research and Technology Science, Pharmacy, Bhopal, India

¹¹Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, Barasat, Kolkata-700126, West Bengal, India

Corresponding Author Email id: sudhanshujh121997@gmail.com

Article Information

Received: 22-12-2025

Revised: 11-01-2026

Accepted: 24-02-2026

Published: 27-03-2026

Keywords

Ocimum sanctum (Tulsi), Cardiovascular diseases, Cardioprotection, Phytochemicals, Antioxidant activity, Clinical evidence

ABSTRACT:

Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, necessitating the exploration of safe and effective alternative therapies. *Ocimum sanctum* (Tulsi), a well-known medicinal plant in traditional systems such as Ayurveda, has gained considerable attention for its potential cardioprotective properties. This review aims to comprehensively evaluate the experimental and clinical evidence supporting the role of Tulsi in cardiovascular health. A systematic literature search was conducted across major databases, including PubMed, Scopus, and Web of Science, focusing on in-vitro, in-vivo, and clinical studies. The findings indicate that Tulsi exhibits significant antioxidant, anti-inflammatory, lipid-lowering, antihypertensive, and anti-atherosclerotic activities, primarily attributed to its rich phytochemical profile, including eugenol, ursolic acid,

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

and flavonoids. Experimental studies demonstrate its ability to reduce oxidative stress, improve endothelial function, and regulate lipid metabolism, while limited clinical studies suggest beneficial effects on blood pressure, lipid profile, and glycemic control. Despite these promising outcomes, challenges such as lack of large-scale clinical trials, variability in extract standardization, and dose inconsistencies remain. Overall, *Ocimum sanctum* holds substantial potential as a complementary therapeutic agent in the prevention and management of cardiovascular diseases, warranting further scientific validation through rigorous clinical investigations.

INTRODUCTION:

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, accounting for nearly 17.9 million deaths annually, representing approximately 32% of global deaths. A significant proportion of these deaths are attributed to coronary artery disease, stroke, and hypertension, particularly in low- and middle-income countries such as India, where rapid urbanization, sedentary lifestyle, and dietary transitions have intensified disease prevalence^{1,2}. The increasing burden of CVDs poses a major challenge to healthcare systems and necessitates the exploration of effective, safe, and affordable therapeutic strategies. Despite remarkable advances in modern pharmacotherapy, including statins, beta-blockers, antiplatelet agents, and angiotensin-converting enzyme (ACE) inhibitors, several limitations persist. These include adverse drug reactions, long-term dependency, high treatment costs, and variable patient compliance. Moreover, conventional drugs often target single pathways, whereas CVDs are multifactorial disorders involving oxidative stress, inflammation, endothelial dysfunction, and lipid abnormalities^{3,4}. These limitations highlight the need for multi-targeted therapeutic approaches with improved safety profiles.

In this context, medicinal plants have gained considerable attention due to their holistic mechanisms of action and long-standing use in traditional medicine systems. Plant-derived phytochemicals such as flavonoids, phenolic acids, alkaloids, and terpenoids exhibit potent antioxidant, anti-inflammatory, and lipid-lowering properties, which are crucial in mitigating cardiovascular risk factors. Increasing scientific evidence supports the cardioprotective potential of herbal medicines, making them promising candidates for integrative and preventive cardiology^{5,6}. Among these, *Ocimum sanctum*, commonly known as Tulsi or Holy Basil, holds a revered position in Ayurveda. It is traditionally recognized as an “adaptogen” and “elixir of life” due to its wide range of therapeutic properties. Tulsi has been extensively used for managing respiratory, metabolic, and inflammatory disorders. Its pharmacological activities are attributed to bioactive compounds such as eugenol, ursolic acid, and rosmarinic acid, which demonstrate significant antioxidant, anti-inflammatory, and cardioprotective effects^{7,8}. Given the increasing interest in plant-based therapeutics and the growing body of experimental and clinical evidence, a comprehensive evaluation of the cardioprotective potential of Tulsi is warranted. Therefore, the present review aims to systematically analyze and integrate available in-vitro, in-vivo, and clinical studies to elucidate the mechanisms, efficacy, and therapeutic relevance of *Ocimum sanctum* in the prevention and management of cardiovascular diseases.

3. Methodology of Review:

This review was conducted following a structured and systematic approach to ensure comprehensive coverage and scientific rigor, aligned with established guidelines such as PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).

Databases Searched:

A comprehensive literature search was performed using major electronic databases, including **PubMed, Scopus, Web of Science, and Google Scholar**. Additional sources such as **ScienceDirect, Cochrane Library, and reference lists of relevant articles** were also screened to identify pertinent studies. This multi-database approach is widely adopted in herbal and cardiovascular systematic reviews to ensure exhaustive retrieval of relevant literature.

Inclusion Criteria:

Studies were included based on the following criteria:

- **Study types:** In-vitro studies, in-vivo animal studies, and human clinical trials
- **Focus:** Studies evaluating the cardioprotective effects of *Ocimum sanctum* (Tulsi)
- **Outcomes:** Cardiovascular parameters such as antioxidant activity, lipid profile, blood pressure, endothelial function, and cardiotoxicity markers
- **Language:** Articles published in English

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

- **Study design:** Randomized controlled trials (RCTs), observational studies, and experimental investigations

The inclusion of diverse study designs is consistent with prior herbal cardiovascular reviews, which integrate preclinical and clinical evidence to provide mechanistic and translational insights.

Exclusion Criteria:

The following studies were excluded:

- Studies not directly related to cardiovascular effects of *Ocimum sanctum*
- Articles lacking full text (e.g., abstracts, editorials, letters)
- Duplicate publications
- Studies focusing on isolated phytochemicals without relevance to whole plant extract
- Non-peer-reviewed sources or studies with insufficient methodological details

Exclusion criteria were defined to ensure reliability and relevance of the included evidence, minimizing bias and improving the quality of synthesis.

Search Strategy:

A systematic search strategy was developed using **Boolean operators (AND, OR)** and combinations of keywords. The primary search terms included:

- “*Ocimum sanctum*” OR “Tulsi” OR “Holy Basil”
- AND “cardioprotective” OR “cardiovascular disease” OR “heart disease”
- AND “antioxidant” OR “anti-inflammatory” OR “lipid profile” OR “hypertension”

The search covered studies published from **2000 to 2025** to capture both foundational and recent advancements in the field. No initial restriction on study design was applied during the search phase to maximize retrieval sensitivity, followed by screening based on eligibility criteria.

The use of structured keyword combinations and iterative refinement of search queries is a standard and effective approach in systematic reviews to ensure comprehensive and reproducible literature identification. Additionally, manual screening of references from selected articles was performed to identify any missed studies.

4. Botanical Profile of *Ocimum sanctum*:

Taxonomy: *Ocimum sanctum* L. (syn. *Ocimum tenuiflorum*), commonly known as Tulsi or Holy Basil, belongs to the family **Lamiaceae**, which comprises aromatic medicinal plants widely used in traditional systems of medicine. Its taxonomic classification is as follows:

- Kingdom: Plantae
- Division: Magnoliophyta
- Class: Magnoliopsida
- Order: Lamiales
- Family: Lamiaceae
- Genus: *Ocimum*
- Species: *Ocimum sanctum* L.

The genus *Ocimum* includes several medicinally important species, among which Tulsi is one of the most therapeutically significant^{9,10}.

Morphological Characteristics: *Ocimum sanctum* is an erect, highly branched, aromatic sub-shrub typically growing to a height of **30–60 cm**. The plant is characterized by:

- **Stem:** Quadrangular, hairy, and green to purplish in color
- **Leaves:** Opposite, ovate, slightly toothed margins, green or purple, strongly aromatic
- **Flowers:** Small, purplish or reddish, arranged in terminal racemes
- **Roots:** Well-developed taproot system
- **Fragrance:** Strong due to essential oil content

Different morphotypes such as **Rama (green leaves)**, **Krishna (purple leaves)**, and **Vana Tulsi** are commonly observed, especially in India and neighboring regions¹¹.

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

Geographical Distribution: *Ocimum sanctum* is native to the Indian subcontinent and is widely distributed throughout tropical and subtropical regions. It is extensively cultivated in countries such as:

- India (major center of cultivation and cultural importance)
- Nepal and Southeast Asian countries
- Malaysia, Australia, and parts of Africa
- Arab countries and other warm climatic regions

The plant thrives in warm climates and is commonly found from plains to moderate altitudes, reflecting its adaptability and widespread medicinal use^{12,13}.

Parts Used: Almost all parts of *Ocimum sanctum* are utilized in traditional and modern medicine due to their rich phytochemical composition:

- **Leaves:** Most commonly used; rich in essential oils and antioxidants
- **Seeds:** Used in traditional formulations and cooling preparations
- **Roots:** Employed in specific therapeutic applications
- **Stems and flowers:** Occasionally used in decoctions and extracts
- **Whole plant:** Sometimes utilized for holistic medicinal preparations

The extensive use of multiple plant parts highlights its broad therapeutic potential, including cardioprotective, anti-inflammatory, and adaptogenic properties^{14,15}.

5. Phytochemical Composition

Table 1: Major Bioactive Compounds and Analytical Techniques

S.No.	Phytochemical Class / Compound	Chemical Nature	Key Pharmacological Activities	Plant Part	Analytical Techniques Used	References
1.	Eugenol	Phenylpropanoid	Antioxidant, anti-inflammatory, anti-platelet, vasodilatory	Leaves (essential oil)	GC-MS, HPLC	[16]
2.	Ursolic Acid	Pentacyclic triterpenoid	Anti-atherosclerotic, anti-inflammatory, lipid-lowering	Leaves, stems	HPLC, LC-MS	[17]
3.	Rosmarinic Acid	Polyphenolic compound	Strong antioxidant, cardioprotective, anti-inflammatory	Leaves	HPLC, LC-MS	[18]
4.	Flavonoids (e.g., Apigenin, Luteolin)	Polyphenols	Free radical scavenging, endothelial protection, anti-hypertensive	Leaves, flowers	HPLC, LC-MS	[19]
5.	Terpenoids (e.g., Ocimene, Caryophyllene)	Volatile organic compounds	Anti-inflammatory, lipid-modulating, cardiotoxic effects	Essential oil (leaves)	GC-MS	[20]

Analytical Techniques

- **High-Performance Liquid Chromatography (HPLC):** Widely used for separation and quantification of non-volatile compounds such as flavonoids, ursolic acid, and rosmarinic acid.
- **Gas Chromatography–Mass Spectrometry (GC-MS):** Preferred for volatile constituents like eugenol and terpenoids present in essential oils.
- **Liquid Chromatography–Mass Spectrometry (LC-MS):** Highly sensitive technique for structural elucidation and precise quantification of phytochemicals.

These analytical tools ensure standardization, quality control, and reproducibility of phytochemical profiling in herbal research¹⁸.

6. Pathophysiology of Cardiovascular Diseases: Cardiovascular diseases (CVDs) are multifactorial disorders involving complex interactions between metabolic, inflammatory, and vascular mechanisms. The major pathological processes contributing to the onset and progression of CVDs include oxidative stress, inflammation, dyslipidemia, endothelial dysfunction, and atherosclerosis.

6.1 Oxidative Stress: Oxidative stress plays a central role in the pathogenesis of CVDs and arises from an imbalance between reactive oxygen species (ROS) production and antioxidant defense systems. Excess ROS leads

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

to lipid peroxidation, protein oxidation, and DNA damage, ultimately impairing vascular integrity and function. Oxidative stress also promotes low-density lipoprotein (LDL) oxidation, a key initiating event in atherogenesis²¹.

6.2 Inflammation: Chronic low-grade inflammation is a hallmark of cardiovascular pathology. Inflammatory mediators such as tumor necrosis factor-alpha (TNF- α), interleukins (IL-6, IL-1 β), and C-reactive protein (CRP) contribute to endothelial injury and plaque formation. Activation of immune cells, including macrophages and T-lymphocytes, further exacerbates vascular inflammation, leading to progression of atherosclerotic lesions²².

6.3 Dyslipidemia: Dyslipidemia, characterized by elevated levels of LDL cholesterol, triglycerides, and reduced high-density lipoprotein (HDL) cholesterol, is a major risk factor for CVDs. Accumulation of lipid particles in arterial walls triggers foam cell formation and fatty streak development, which are early features of atherosclerosis. Abnormal lipid metabolism significantly accelerates vascular damage and plaque instability²³.

6.4 Endothelial Dysfunction: Endothelial dysfunction is an early and critical event in cardiovascular disease progression. It is characterized by reduced bioavailability of nitric oxide (NO), increased oxidative stress, and impaired vasodilation. Dysfunctional endothelium promotes leukocyte adhesion, platelet aggregation, and vascular smooth muscle proliferation, contributing to vascular stiffness and hypertension²⁴.

6.5 Atherosclerosis Progression: Atherosclerosis is a chronic inflammatory disease involving the gradual buildup of lipids, fibrous elements, and immune cells within arterial walls. The process begins with endothelial injury and LDL oxidation, followed by monocyte infiltration and foam cell formation. Over time, plaque maturation leads to narrowing of arteries and reduced blood flow. Plaque rupture can result in thrombosis, leading to acute cardiovascular events such as myocardial infarction and stroke²⁵.

7. Mechanisms of Cardioprotective Action of Tulsi:




Figure 1: Multi-targeted cardioprotective mechanisms of *Ocimum sanctum* mediated through antioxidant, anti-inflammatory, lipid-lowering, and endothelial protective pathways

7.0 Mechanisms of Cardioprotective Action of *Ocimum sanctum*

7.1 Antioxidant Activity

The cardioprotective potential of *Ocimum sanctum* is strongly attributed to its potent antioxidant properties. Tulsi contains bioactive compounds such as eugenol, rosmarinic acid, and flavonoids, which act as effective free radical scavengers. These compounds neutralize reactive oxygen species (ROS), thereby reducing oxidative stress and preventing lipid peroxidation in cardiac tissues. Additionally, Tulsi enhances endogenous antioxidant defense systems by upregulating enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase, contributing to cellular protection and improved cardiac function²⁶.

7.2 Anti-inflammatory Effects:

Chronic inflammation plays a crucial role in cardiovascular disease progression. *Ocimum sanctum* exhibits significant anti-inflammatory activity by modulating key inflammatory mediators. It has been shown to reduce the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α) and interleukin-6 (IL-6), primarily through inhibition of the NF- κ B signaling pathway. This cytokine modulation helps in reducing vascular inflammation, thereby preventing endothelial damage and atherosclerotic progression²⁷.

7.3 Lipid-Lowering Effects:

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

Tulsi demonstrates hypolipidemic activity by regulating lipid metabolism. Experimental studies have reported a significant reduction in serum levels of low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), and triglycerides, along with an increase in high-density lipoprotein (HDL). These effects contribute to the prevention of lipid accumulation in arterial walls, thereby reducing the risk of atherosclerosis and coronary artery disease ²⁸.

7.4 Anti-hypertensive Activity:

The antihypertensive effects of *Ocimum sanctum* are mediated through multiple mechanisms, including vasodilation and modulation of the renin–angiotensin system. Tulsi enhances nitric oxide (NO) bioavailability, leading to relaxation of vascular smooth muscles and improved blood flow. Additionally, certain phytoconstituents exhibit angiotensin-converting enzyme (ACE) inhibitory activity, which helps in regulating blood pressure and reducing cardiac workload ²⁹.

7.5 Anti-atherosclerotic Effects:

Tulsi exerts anti-atherosclerotic effects by preventing plaque formation and promoting vascular health. It inhibits the oxidation of LDL cholesterol, reduces foam cell formation, and stabilizes existing atherosclerotic plaques. Furthermore, its endothelial protective effects help maintain vascular integrity by improving endothelial function and reducing adhesion molecule expression, thereby limiting the progression of atherosclerosis ³⁰.

8. Experimental Evidence:

8.1 In-vitro Studies:

Cellular Antioxidant Assays: In-vitro studies have demonstrated that *Ocimum sanctum* exhibits potent antioxidant activity through various cellular and biochemical assays such as DPPH, ABTS, and nitric oxide scavenging assays. These studies confirm the ability of Tulsi extracts to neutralize reactive oxygen species (ROS) and inhibit lipid peroxidation, thereby protecting cellular components from oxidative damage. The antioxidant potential is primarily attributed to phenolic compounds such as eugenol, rosmarinic acid, and flavonoids ³¹.

Endothelial Cell Protection Studies: Tulsi extracts have shown protective effects on vascular endothelial cells by reducing oxidative stress-induced damage. In endothelial cell line studies, *Ocimum sanctum* improved nitric oxide (NO) bioavailability and reduced oxidative injury, thereby enhancing endothelial function. These findings suggest its role in preventing endothelial dysfunction, a key early event in cardiovascular diseases ³².

8.2 In-vivo Studies

Animal Models of Myocardial Infarction: In-vivo studies using animal models have demonstrated significant cardioprotective effects of *Ocimum sanctum* in myocardial infarction conditions. Tulsi extracts have been shown to reduce infarct size, improve cardiac function, and normalize biochemical markers in experimentally induced myocardial injury. These effects are largely mediated through antioxidant and anti-inflammatory mechanisms ³³.

Isoproterenol-Induced Cardiotoxicity Models: Isoproterenol-induced cardiotoxicity is a widely used experimental model to mimic myocardial infarction. Studies have reported that administration of *Ocimum sanctum* extract significantly attenuates isoproterenol-induced myocardial damage by reducing oxidative stress, preventing lipid peroxidation, and preserving myocardial tissue architecture. It also helps in restoring normal cardiac enzyme levels ³⁴.

Lipid Profile and Enzyme Markers (CK-MB, LDH): Several in-vivo studies have demonstrated that Tulsi improves lipid profiles by decreasing serum levels of total cholesterol, LDL, triglycerides, and increasing HDL levels. Additionally, it significantly reduces cardiac injury markers such as creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH), indicating reduced myocardial damage and enhanced cardiac protection ³⁵.

9. Clinical Evidence: Tulsi demonstrates multi-targeted cardio-protective effects in humans, particularly in regulating blood pressure, lipid profile, and glucose metabolism. Its adapto-genic and antioxidant properties contribute to overall cardiovascular health. Clinical studies consistently report high safety and tolerability, supporting its use as a complementary therapy.

Table 2: Summary of Human Trials, Cardiovascular Effects, and Safety

S.No	Study Type / Population	Intervention (Tulsi Formulation)	Observed Effects	Cardiovascular Relevance	Safety & Tolerability	References
------	-------------------------	----------------------------------	------------------	--------------------------	-----------------------	------------

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

1.	Human clinical trial (healthy & mildly stressed individuals)	Tulsi leaf extract (capsules/aqueous extract)	Reduction in blood pressure and stress markers	Anti-hypertensive, adaptogenic effect	Well tolerated; no major adverse effects reported	[36]
2.	Human study (metabolic syndrome / hyperlipidemia patients)	Tulsi leaf powder/extract	↓ Total cholesterol, LDL, triglycerides; ↑ HDL	Lipid-lowering, anti-atherosclerotic effect	Safe with prolonged use	[37]
3.	Clinical trial (type 2 diabetes patients)	Tulsi leaf extract	↓ Blood glucose levels (fasting & postprandial)	Indirect cardioprotection via glycemic control	No significant toxicity observed	[38]
4.	Human trial (hypertensive individuals)	Tulsi supplementation	Mild to moderate reduction in systolic and diastolic BP	Supports vascular relaxation and BP regulation	Good compliance, minimal side effects	[39]
5.	General clinical observations (various populations)	Tulsi formulations (tea, extract, capsules)	Improved antioxidant status and reduced inflammation	Reduces cardiovascular risk factors	Considered safe in recommended doses	[40]

10. Comparative Analysis with Conventional Drugs

10.1 Comparative Analysis with Conventional Drugs

a) Tulsi vs. Statins, Beta-Blockers, and ACE Inhibitors: *Ocimum sanctum* (Tulsi) demonstrates a broad spectrum of cardioprotective effects that can be compared with conventional pharmacological agents such as statins, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors. Statins primarily act by inhibiting HMG-CoA reductase to reduce cholesterol levels, whereas beta-blockers decrease heart rate and myocardial oxygen demand, and ACE inhibitors regulate blood pressure through the renin–angiotensin system. In contrast, Tulsi exerts **multi-targeted effects**, including antioxidant, anti-inflammatory, lipid-lowering, and vasodilatory actions. Unlike statins, which may cause adverse effects such as myopathy and hepatotoxicity, Tulsi has shown a favorable safety profile in both experimental and clinical studies. Additionally, Tulsi’s ability to modulate oxidative stress and inflammation provides broader protection against endothelial dysfunction and atherosclerosis, beyond the single-target mechanisms of conventional drugs ⁴¹.

b) Synergistic Potential: Tulsi exhibits significant potential for **synergistic use with conventional cardiovascular drugs**. Its antioxidant and anti-inflammatory properties may enhance the therapeutic efficacy of statins and ACE inhibitors by reducing oxidative damage and improving endothelial function. Furthermore, Tulsi’s adaptogenic effects may help in mitigating stress-related cardiovascular risk factors, complementing the pharmacological action of beta-blockers. Emerging evidence suggests that combining herbal therapies with standard medications may allow for **dose reduction**, minimizing adverse effects while maintaining therapeutic efficacy. However, careful evaluation of herb–drug interactions is essential to ensure safety and optimize clinical outcomes ⁴².

Advantages (Natural, Multi-targeted Action): Tulsi offers several advantages over conventional drugs:

- **Multi-targeted mechanism:** Acts on oxidative stress, inflammation, lipid metabolism, and vascular function simultaneously
- **Natural origin:** Derived from plant sources with long-standing traditional use in Ayurveda
- **Favorable safety profile:** Minimal side effects reported in clinical and experimental studies
- **Adaptogenic properties:** Helps in stress reduction, indirectly benefiting cardiovascular health
- **Cost-effectiveness:** Accessible and affordable, especially in developing countries

These advantages position Tulsi as a promising adjunct or alternative in integrative cardiovascular therapy, particularly for long-term disease prevention and management ⁴³.

11. Safety, Toxicity, and Dosage:

11.1 Acute and Chronic Toxicity Studies:

Ocimum sanctum has been extensively evaluated for safety in both acute and chronic toxicity studies. Preclinical investigations indicate that Tulsi extracts possess a **high margin of safety**, with no significant mortality or toxic effects observed even at higher doses in animal models. Acute toxicity studies have reported that Tulsi is well tolerated, with LD₅₀ values suggesting low toxicity.

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

Chronic toxicity studies further demonstrate that long-term administration of Tulsi does not produce significant alterations in hematological, biochemical, or histopathological parameters. These findings support its safety for prolonged therapeutic use. However, very high doses may lead to mild gastrointestinal disturbances or alterations in reproductive parameters in experimental settings, indicating the need for dose optimization ⁴⁴.

11.2 Recommended Dosage Forms

Tulsi is available in various traditional and modern dosage forms, each offering specific advantages:

- **Aqueous extract (decoction/tea):** Commonly used in traditional medicine; suitable for daily consumption
- **Powder (Churna):** Typically administered in doses of 1–3 g/day
- **Capsules/Tablets (standardized extracts):** Usually 300–600 mg, taken 1–2 times daily depending on extract concentration
- **Essential oil:** Used in very small quantities due to high potency

Standardization of active constituents such as eugenol is essential to ensure consistency, efficacy, and safety of formulations. Dosage may vary depending on therapeutic indication, patient condition, and formulation type ^{45, 46}.

11.3 Drug–Herb Interactions:

Although Tulsi is generally considered safe, potential herb–drug interactions should be taken into account:

- **Anticoagulants/Antiplatelet drugs:** Tulsi may enhance blood-thinning effects due to its eugenol content
- **Antihypertensive drugs:** Additive effects may lead to excessive lowering of blood pressure
- **Antidiabetic medications:** May potentiate hypoglycemic effects
- **Cytochrome P450 modulation:** Tulsi may influence drug metabolism pathways, affecting drug bioavailability

Therefore, caution is advised when Tulsi is co-administered with conventional medications, and clinical monitoring is recommended to avoid adverse interactions ⁴⁷.

12. Formulation and Delivery Approaches




Figure 2: Comprehensive schematic representation of formulation and delivery strategies of *Ocimum sanctum*, illustrating the transition from traditional preparations to advanced nano-formulations and transdermal systems for enhanced bioavailability and targeted cardio-protective action.

12.0 Transdermal Drug Delivery Systems (TDDS): Mechanisms of Permeation Enhancement

The pictorial illustrates the mechanisms of drug permeation across the skin via Transdermal Drug Delivery Systems (TDDS), categorized into active and passive approaches, along with the skin structure involved in drug transport.

12.1 Skin Structure and Drug Permeation Pathway

The skin acts as a biological barrier comprising three primary layers:

- **Epidermis (Stratum corneum – major barrier)**

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

- **Dermis (vascularized region for systemic absorption)**
- **Adipose tissue (subcutaneous layer)**

Drug molecules applied via TDDS penetrate through the stratum corneum, diffuse across the epidermis and dermis, and finally enter systemic circulation via dermal blood vessels. The efficiency of this process depends on molecular size, lipophilicity, and formulation strategy [48].

12.2 Active Approaches (Energy-Driven Enhancement)

Microneedles

- Create microchannels in the skin
- Enhance permeability without significant pain
- Suitable for macromolecules and phytoconstituents

Transdermal Patch (Controlled Delivery)

- Maintains sustained drug release
- Ensures consistent plasma concentration

Electrophoresis (Iontophoresis)

- Uses electric current to drive charged molecules across skin
- Improves penetration of polar compounds

Sonophoresis (Ultrasound-mediated)

- Uses ultrasonic waves to disrupt lipid bilayers
- Enhances drug diffusion and permeability

These active techniques overcome the barrier function of the stratum corneum, significantly improving drug bioavailability⁴⁹.

12.3 Passive Approaches (Carrier-Based Enhancement):

Liposomes:

- Phospholipid vesicles encapsulating drug molecules
- Enhance penetration by merging with skin lipids

Solid Lipid Nanoparticles (SLNs):

- Provide controlled release
- Improve drug stability and skin retention

Nano-lipid Carriers

- Enhance drug solubility and permeation
- Improve bioavailability of lipophilic phytochemicals

Dendrimers:

- Branched polymeric nanocarriers
- Facilitate targeted and controlled drug delivery

Passive approaches rely on carrier systems to enhance drug transport without external energy input, making them suitable for sustained and non-invasive delivery⁵⁰.

12.4 Integrated Permeation Mechanism:

The overall mechanism involves:

Formulation (Patch/Nano-carrier) → Skin Barrier Modulation → Enhanced Diffusion → Systemic Absorption

Both active and passive approaches can be combined to achieve **synergistic enhancement of drug permeation**, particularly for phytochemicals with poor bioavailability, such as those present in *Ocimum sanctum*.

12.5 Relevance to Herbal Drug Delivery (Tulsi):

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

For phytochemicals like **eugenol, ursolic acid, and flavonoids**, TDDS offers:

- Improved bioavailability
- Sustained release
- Avoidance of first-pass metabolism
- Targeted cardiovascular benefits

This aligns strongly with advanced research approaches, including transdermal patches for herbal cardio-protective agents ⁵¹.

13. Limitations of Current Studies:

Limitations of Current Studies:

Despite the promising cardioprotective potential of *Ocimum sanctum* (Tulsi), several limitations in the existing body of research restrict its translation into mainstream clinical practice.

Lack of Large-Scale Clinical Trials:

Most of the available evidence on Tulsi is derived from **in-vitro experiments and small-scale clinical studies**, with limited large, randomized controlled trials (RCTs). The absence of multicentric, large-population studies reduces the generalizability and statistical strength of the findings. Consequently, definitive conclusions regarding its efficacy in cardiovascular disease management remain constrained ⁵².

Variability in Extract Standardization:

A significant challenge in herbal research is the **lack of uniform standardization of plant extracts**. Studies on *Ocimum sanctum* utilize different extraction methods (aqueous, ethanolic, hydroalcoholic) and varying concentrations of active constituents such as eugenol and ursolic acid. This variability leads to inconsistencies in pharmacological outcomes and makes inter-study comparisons difficult ⁵³.

Dose Inconsistency:

There is considerable variation in the **dosage regimens** used across experimental and clinical studies. Differences in formulation type (powder, extract, capsule) and dosing frequency hinder the establishment of an optimal therapeutic dose. The absence of standardized dosing guidelines limits its clinical applicability and reproducibility of results ⁵⁴.

Short Study Durations:

Many studies investigating the cardioprotective effects of Tulsi are conducted over **short durations**, which may not adequately reflect long-term efficacy and safety. Cardiovascular diseases are chronic conditions requiring prolonged management; hence, short-term studies fail to capture sustained therapeutic outcomes and potential long-term adverse effects ⁵⁵.

14. Future Perspectives:

Future research on *Ocimum sanctum* (Tulsi) should prioritize the conduct of well-designed, large-scale randomized controlled trials to establish definitive clinical efficacy and safety in cardiovascular disease management, as current evidence remains limited and heterogeneous. Standardization of phytochemical composition, particularly key bioactive constituents such as eugenol, ursolic acid, and rosmarinic acid, is essential to ensure reproducibility, quality control, and consistent therapeutic outcomes across studies. Additionally, the integration of advanced technologies such as artificial intelligence and machine learning can significantly accelerate herbal drug discovery by enabling predictive modelling, target identification, and optimization of phytochemical interactions. Furthermore, the concept of personalized herbal medicine, which tailors treatment based on individual genetic, metabolic, and lifestyle factors, holds promise in enhancing the precision and effectiveness of Tulsi-based interventions. Collectively, these approaches can bridge the gap between traditional knowledge and modern evidence-based medicine, facilitating the development of standardized, clinically validated, and patient-centric cardio-protective therapies.

CONCLUSION:

In conclusion, *Ocimum sanctum* (Tulsi) emerges as a promising natural cardioprotective agent with multi-targeted mechanisms of action, including antioxidant, anti-inflammatory, lipid-regulating, and endothelial-protective effects. The integration of experimental and clinical evidence highlights its potential role in mitigating key risk factors associated with cardiovascular diseases, such as oxidative stress, dyslipidemia, hypertension, and

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

inflammation. Compared to conventional pharmacotherapy, Tulsi offers advantages such as a favorable safety profile, cost-effectiveness, and holistic therapeutic action; however, its clinical translation is limited by insufficient large-scale randomized trials, lack of standardized formulations, and variability in dosing regimens. Future research focusing on phytochemical standardization, advanced drug delivery systems, and integration with emerging technologies such as artificial intelligence and personalized medicine could significantly enhance its therapeutic applicability. Therefore, while Tulsi demonstrates strong potential as an adjunct or alternative in cardiovascular management, robust scientific validation and regulatory standardization are essential to establish its role in evidence-based clinical practice.

REFERENCES:

- World Health Organization. Cardiovascular diseases (CVDs) fact sheet. 2023.
- Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases. *J Am Coll Cardiol*. 2020;76(25):2982–3021.
- Libby P. Inflammation in atherosclerosis. *Nature*. 2002;420:868–874.
- Yusuf S, Hawken S, Ounpuu S, et al. Effect of modifiable risk factors. *Lancet*. 2004;364:937–952.
- Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants. *Oxid Med Cell Longev*. 2009;2(5):270–278.
- Williamson EM. Synergy and other interactions in phytomedicines. *Phytomedicine*. 2001;8(5):401–409.
- Pattanayak P, Behera P, Das D, Panda SK. *Ocimum sanctum* Linn.: A review. *Pharmacogn Rev*. 2010;4(7):95–105.
- Cohen MM. Tulsi – *Ocimum sanctum*: A herb for all reasons. *J Ayurveda Integr Med*. 2014;5(4):251–259.
- Pattanayak P, Behera P, Das D, Panda SK. *Ocimum sanctum* Linn.: A review. *Pharmacogn Rev*. 2010;4(7):95–105. (PMC)
- Sharma A, et al. Description and taxonomy of *Ocimum sanctum*. *Bioprospective Review*. 2023. (PMC)
- Singh S, et al. Morphological characterization of Tulsi. *Int J Res Appl Sci Biotechnol*. 2022. (ResearchGate)
- Ocimum* species distribution and significance. *PMC Review*. 2022. (PMC)
- Mondal S, et al. Global distribution and medicinal uses of *Ocimum*. *PMC Review*. 2021. (PMC)
- Wal A, Verma N, Balakrishnan SK, et al. Herbal interventions in cardiovascular diseases: A systematic review. *Curr Cardiol Rev*. 2024. (PubMed)
- Jamshidi N, Cohen MM. Clinical efficacy and safety of Tulsi: A systematic review. *Evid Based Complement Alternat Med*. 2017. (PubMed)
- Pattanayak P, Behera P, Das D, Panda SK. *Ocimum sanctum* Linn.: A review. *Pharmacogn Rev*. 2010;4(7):95–105.
- Cohen MM. Tulsi – *Ocimum sanctum*: A herb for all reasons. *J Ayurveda Integr Med*. 2014;5(4):251–259.
- Prakash P, Gupta N. Therapeutic uses of *Ocimum sanctum* Linn. *Int J Clin Pharmacol Ther*. 2005;43(4):162–165.
- Mondal S, et al. Phytochemical analysis and therapeutic potential of *Ocimum*. *J Food Sci Technol*. 2021.
- Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants. *Oxid Med Cell Longev*. 2009;2(5):270–278.
- Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. *Arterioscler Thromb Vasc Biol*. 2005;25(1):29–38.
- Peter Libby. Inflammation in atherosclerosis. *Nature*. 2002; 420:868–874.
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005; 352:1685–1695.
- World Health Organization. Cardiovascular diseases (CVDs) fact sheet. 2023.
- Endemann DH, Schiffrin EL. Endothelial dysfunction. *J Am Soc Nephrol*. 2004;15(8):1983–1992.
- Pattanayak P, Behera P, Das D, Panda SK. *Ocimum sanctum* Linn.: A review. *Pharmacogn Rev*. 2010;4(7):95–105.
- Marc Maurice Cohen. Tulsi – *Ocimum sanctum*: A herb for all reasons. *J Ayurveda Integr Med*. 2014;5(4):251–259.
- Prakash P, Gupta N. Therapeutic uses of *Ocimum sanctum* Linn. *Int J Clin Pharmacol Ther*. 2005;43(4):162–165.
- Mondal S, et al. Phytochemical and pharmacological profile of *Ocimum sanctum*. *J Food Sci Technol*. 2021.
- Jamshidi N, Cohen MM. Clinical efficacy of Tulsi: A systematic review. *Evid Based Complement Alternat Med*. 2017.
- Pattanayak P, Behera P, Das D, Panda SK. *Ocimum sanctum* Linn.: A review. *Pharmacogn Rev*. 2010;4(7):95–105.
- Marc Maurice Cohen. Tulsi – *Ocimum sanctum*: A herb for all reasons. *J Ayurveda Integr Med*. 2014;5(4):251–259.
- Singh N, Hoette Y, Miller R. Tulsi: The Mother Medicine of Nature. *J Ayurveda Integr Med*. 2010.
- Devi PU, Ganasoundari A. Radioprotective effect of *Ocimum sanctum*. *Indian J Exp Biol*. 1999.
- Jamshidi N, Cohen MM. Clinical efficacy of Tulsi: A systematic review. *Evid Based Complement Alternat Med*. 2017.
- Saxena RC, Singh R, Kumar P, et al. Evaluation of Tulsi in stress and cardiovascular parameters. *Indian J Pharmacol*. 2012.
- Marc Maurice Cohen. Tulsi – *Ocimum sanctum*: A herb for all reasons. *J Ayurveda Integr Med*. 2014;5(4):251–259.
- Agrawal P, Rai V, Singh RB. Randomized controlled trial of *Ocimum sanctum* in metabolic disorders. *J Assoc Physicians India*. 1996.
- Jamshidi N, Cohen MM. Clinical efficacy and safety of Tulsi: A systematic review. *Evid Based Complement Alternat Med*. 2017.
- Mondal S, et al. Therapeutic potential of *Ocimum sanctum*: A review. *J Food Sci Technol*. 2021.
- Marc Maurice Cohen. Tulsi – *Ocimum sanctum*: A herb for all reasons. *J Ayurveda Integr Med*. 2014;5(4):251–259.
- Jamshidi N, Cohen MM. Clinical efficacy and safety of Tulsi: A systematic review. *Evid Based Complement Alternat Med*. 2017.
- Williamson EM. Synergy and other interactions in phytomedicines. *Phytomedicine*. 2001;8(5):401–409.
- Pattanayak P, Behera P, Das D, Panda SK. *Ocimum sanctum* Linn.: A review. *Pharmacogn Rev*. 2010;4(7):95–105.
- Marc Maurice Cohen. Tulsi – *Ocimum sanctum*: A herb for all reasons. *J Ayurveda Integr Med*. 2014;5(4):251–259.
- Jamshidi N, Cohen MM. Clinical efficacy and safety of Tulsi: A systematic review. *Evid Based Complement Alternat Med*. 2017.
- Williamson EM. Drug interactions between herbal and conventional medicines. *Phytother Res*. 2001;15(7):587–593.
- Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol*. 2008;26(11):1261–1268.
- Ita K. Transdermal delivery of drugs with microneedles. *Drug Deliv Transl Res*. 2015;5(4):424–442.
- Cevc G, Vierl U. Nanotechnology and transdermal drug delivery. *J Control Release*. 2010;141(3):277–299.
- Kaur LP, Guleri TK. Topical and transdermal drug delivery systems: Review. *Int J Pharm Sci Rev Res*. 2013;19(1):36–44.
- Jamshidi N, Cohen MM. Clinical efficacy and safety of Tulsi: A systematic review. *Evid Based Complement Alternat Med*. 2017.
- Marc Maurice Cohen. Tulsi – *Ocimum sanctum*: A herb for all reasons. *J Ayurveda Integr Med*. 2014;5(4):251–259.
- Williamson EM. Synergy and other interactions in phytomedicines. *Phytomedicine*. 2001;8(5):401–409.
- Gagnier JJ, et al. Challenges in herbal medicine research. *J Clin Epidemiol*. 2006;59(12):1224–1231.

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)